Skip to main content
Unchecking box will stop auto data updates
TSX Venture Real-Time Last Sale CAD
Today's Change
Price Quote as of

Today's Trading

Day Low 2.380
Day High 2.530
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Khiron Life Sciences Corp is a Canada based company involved in cultivating, producing, and distributing THC (tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. Some of the potential uses for medicinal cannabis are disease treatment, pain relief, and disease prevention, including: treatment of epilepsy; slow cell damage in diabetes glaucoma, lower intraocular pressure; treatment of Tourette syndrome among others.


Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio


Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Khiron Announces Changes to Leadership Team with Appointment of Wendy Kaufman as CFO
PR Newswire - Fri Jun 14, 5:56AM CDT
PR Newswire - PRNW
Fri Jun 14, 5:56AM CDT
TORONTO , June 14, 2019 /PRNewswire/ - Khiron Life Sciences Corp. (" Khiron " or the " Company ") (TSXV: KHRN), (OTCQB: KHRNF), ( Frankfurt : A2JMZC), a cannabis company with core operations in Latin America , today announced the appointment of Wendy Kaufman as CFO, effective July 2, 2019 . Ms. Kaufman, a Chartered Professional Accountant, brings over 20 years of international financial experience, having served most recently as CFO at Pasinex Resources Limited.  Ms. Kaufman has significant experience with Latin American operations, gained during her tenure as CFO at Primero Mining Corporation, and previously in her role as Vice President, Finance and Treasury at Inmet Mining Corporation, among other executive management positions.
Cannabis Consumers Reap the Benefits of Lower Cultivation Costs
PR Newswire - Wed Jun 12, 8:00AM CDT
PR Newswire - CMTX
Wed Jun 12, 8:00AM CDT
Legal cannabis can be quite expensive for consumers, however, regions that have adopted legislation early on tend to generally have lower prices. The most expensive price per gram is found within countries where illegal sales are still the only way to get cannabis. And the most expensive cannabis can be found predominantly in Asian countries such as Japan, South Korea, and China, where cannabis is strictly prohibited. In particular, illicitly traded cannabis in Tokyo, Japan can cost as much as USD 32 per gram. On the other hand, the price per gram is as low as USD 1.34 in Quito, Ecuador. Interestingly, Ecuador has not legalized cannabis for either recreational or medical use but instead, the Country has decriminalized up to 10 grams of flower for personal use. Similarly, other South American regions such as Bogota, Colombia and areas of Paraguay have priced their cannabis supply at roughly USD 2.20 per gram, according to Leafly. The prices are significantly cheaper in South America, even though several U.S. states had allowed medicinal cannabis by the turn of the century. In the U.S., cannabis prices are cheapest in Denver, Colorado and Seattle, Washington, which were the first two states to legalize recreational use. However, their prices are nearly triple or quadruple what they are in South American regions. Seattle, on average, sells each gram of cannabis for about USD 7.58, while Denver priced each gram at approximately USD 7.79. Even in U.S. markets where cannabis is completely legal, the prices are still extraordinarily high compared to South America. Washington D.C., the capital of the U.S., sells each gram for about USD 18.08, which is over 1200% higher than Quito, Ecuador. Moreover, Canada has experienced its cannabis prices increase by 17% just several months after legalization. Statistics Canada reported that some provinces witnessed the price jump from USD 6.83 to USD 8.02 per gram, while legal adult-use cannabis can cost as much as USD 9.70 per gram. Prices within the cannabis marketplace are still relatively high because the industry remains within a gray area. Nonetheless, as countries within the marketspace continue to mature, consumers can expect prices to drop dramatically. According to data compiled by Mordor Intelligence, the global cannabis market was valued USD 14.5 Billion in 2018. By 2024, the market is projected to reach USD 89.1 Billion while registering a CAGR of 37% during the forecast period from 2019 to 2024. Blueberries Medical Corp. (OTC: BBRRF) (CSE: BBM), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), Aphria Inc. (NYSE: APHA) (TSX: APHA), PharmaCielo Ltd. (OTC: PHCEF) (TSX-V: PCLO), Khiron Life Sciences Corp. (OTC: KHRNF) (TSX-V: KHRN)
Khiron Receives Regulatory Approval for Uruguay Acquisition
PR Newswire - Thu Jun 6, 11:01PM CDT
PR Newswire - PRNW
Thu Jun 6, 11:01PM CDT
TORONTO , June 7, 2019 /PRNewswire/ - Khiron Life Sciences Corp. (" Khiron " or the " Company ") (TSXV: KHRN), (OTCQB: KHRNF), ( Frankfurt : A2JMZC), a medical cannabis company with core operations in Latin America reports that the Company's previously announced agreement for the acquisition (the " Acquisition ") of NettaGrowth International Inc. (" NettaGrowth "), which at closing will own all of the outstanding shares of a Uruguayan company, Dormul S.A. (" Dormul "), is progressing as planned.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 2.380 +0.42% increase
on 06/17/19
Period Open:3.300
Price movement based on the high, low and last over the given period.
3.320 -28.01% decrease
on 05/22/19
-0.910 (-27.58%) decrease
since 05/17/19
3-Month 2.380 +0.42% increase
on 06/17/19
Period Open:3.700
Price movement based on the high, low and last over the given period.
4.260 -43.90% decrease
on 03/19/19
-1.310 (-35.41%) decrease
since 03/15/19
52-Week 0.870 +174.71% increase
on 08/01/18
Period Open:1.200
Price movement based on the high, low and last over the given period.
4.350 -45.06% decrease
on 02/22/19
+1.190 (+99.17%) increase
since 06/15/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).